IMMUNIC Seeks Shareholder Approval for Reverse Stock Split to Maintain Nasdaq Listing and Fulfill $200M Financing Obligation
IMUX sits 87% above its 52-week low of $0.506.
Summary
Immunic, Inc. is seeking shareholder approval for a reverse stock split (1-for-10 to 1-for-30) to meet Nasdaq's minimum bid price requirement and satisfy a key condition of its recent $200 million private placement.
Key Events · Corporate Governance and Compliance · IMUX
-
Shareholder Vote on Reverse Stock Split
The company is calling a special meeting for stockholders to vote on authorizing the Board of Directors to effect a reverse stock split at a ratio between 1-for-10 and 1-for-30.
-
Nasdaq Listing Compliance
The reverse stock split is intended to increase the per-share trading price to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the June 22, 2026 deadline, following its transfer to the Nasdaq Capital Market.
-
Condition of Recent $200M Financing
Approval of the reverse stock split is a mandatory obligation under the securities purchase agreement for the $200 million private placement that closed on February 17, 2026. Failure to obtain approval would result in a breach of this critical financing agreement.
Analysis · IMUX · Life Sciences
Immunic, Inc. is seeking shareholder approval for a reverse stock split, a critical step to address its non-compliance with Nasdaq's minimum bid price requirement. The company previously transferred its listing to the Nasdaq Capital Market (as disclosed in the 8-K on 2026-01-06) and faces a June 22, 2026 deadline to regain compliance. More importantly, this proxy statement reveals that obtaining shareholder approval for the reverse stock split is a mandatory obligation under the recent $200 million private placement agreement (announced in the 8-K on 2026-02-13). Failure to secure this approval would put the company in breach of the financing terms, which would have severe adverse effects on its business and operations. While a reverse stock split is generally viewed negatively as it often signals underlying issues, in this case, it is a necessary defensive measure to ensure continued listing and, crucially, to uphold a significant capital raise that is vital for the company's runway.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 41.2% of the 452 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMUX was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $113.1M. The 52-week trading range was $0.51 to $1.39. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.